Litcius/Paper detail

Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study

Cora N. Sternberg, Daniel Castellano, Johann S. de Bono, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean‐Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Elizabeth M. Poole, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Ronald de Wit

2021European Urology25 citationsDOIOpen Access PDF

Topics & Concepts

CabazitaxelEnzalutamideMedicineProstate cancerPrednisoneHazard ratioDocetaxelInternal medicineUrologyOncologyConfidence intervalCancerAndrogen deprivation therapyAndrogen receptorProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study | Litcius